1
|
van der Valk JPM, Hekking PP, Rauh SP, Patberg KW, van Veen HPAA, Van Huisstede A, Smeenk FWJM, van de Ven MJT, Broeders MEAC, Hilvering B, van Exsel J, Oud KTM, Langeveld B, Fieten KB, van Veen A, Hashimoto S, Sont JK, Brinke AT, Braunstahl GJ. Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma: A RAPSODI registry-based cohort study. J Asthma 2023:1-8. [PMID: 36976568 DOI: 10.1080/02770903.2023.2196563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
Abstract
INTRODUCTION Severe asthma is associated with a serious disease burden, partially caused by limitations in activity and work impairment (1,2). AIMS AND OBJECTIVES This study aims to relate treatment with biologics targeting IL-5/5Ra to work productivity and activity in the long term in a real-world context. MATERIAL AND METHODS This is a registry-based multi-center cohort study evaluating data from adults with severe eosinophilic asthma included in the Dutch Register of Adult Patients with Severe Asthma for Optimal DIsease management (RAPSODI). Patients that started with anti-IL-5/5Ra biologics and completed the work productivity and activity improvement questionnaire, were included. Study and patient characteristics were compared between the employed and unemployed patients. Work productivity and activity impairment are related to accompanying improvements in clinical outcomes. RESULTS At baseline, 91 of 137 patients (66%) were employed which remained stable throughout the follow-up period. Patients in the working age category were younger and had significantly better asthma control (p =0.02). Mean overall work impairment due to health decreased significantly from 25.5% (SD2.6) to 17.6% (SD 2.8) during 12 months anti-IL-5/5Ra biologics treatment (P = 0.010). There was a significant association between ACQ6 and overall work improvement after targeted therapy (β =8.7, CI 2.1-15.4, P = 0.01). The improvement of asthma control of 0.5 points on the asthma Control Questionnaire was associated with an overall work impairment of - 9%. CONCLUSIONS Work productivity and activity in severe eosinophilic asthma improved after starting anti-IL-5/5Ra biologics. Clinically relevant improvement in asthma control was associated with an overall work impairment score of - 9% in this study.
Collapse
Affiliation(s)
- J P M van der Valk
- Department of Pulmonary Medicine, STZ Center of Excellence for Asthma and COPD, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
| | - P P Hekking
- Department of Pulmonary Medicine, STZ Center of Excellence for Asthma and COPD, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
| | - S P Rauh
- Department of science, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
| | - K W Patberg
- Department of Pulmonary Medicine, Isala, Zwolle, The Netherlands
| | - H P A A van Veen
- Department of Pulmonary Medicine, Medical Center Twente, The Netherlands
| | - A Van Huisstede
- Department of Pulmonary Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - F W J M Smeenk
- Department of Pulmonary Medicine, Catharina Hospital, Eindhoven, The Netherlands
| | - M J T van de Ven
- Department of Pulmonary Medicine, Rijnstate, Arnhem, The Netherlands
| | - M E A C Broeders
- Department of Pulmonary Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
| | - B Hilvering
- Department of Pulmonary Medicine, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands
| | - J van Exsel
- Department of Pulmonary Medicine, Haga Hospital, The Hague, The Netherlands
| | - K T M Oud
- Department of Pulmonary Medicine, Hospital Gelderse Vallei, Ede, The Netherlands
| | - B Langeveld
- Department of Pulmonary Medicine, Deventer Hospital, Deventer, The Netherlands
| | - K B Fieten
- Dutch Asthma Center Davos, Davos, Switzerland
| | - A van Veen
- Department of Pulmonary Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | - S Hashimoto
- Department of Pulmonary Medicine, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands
| | - J K Sont
- Department of Biomedical Data Science, Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands
| | - A Ten Brinke
- Department of Pulmonary Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherland
| | - G J Braunstahl
- Department of Pulmonary Medicine, STZ Center of Excellence for Asthma and COPD, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
- Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands
| | | |
Collapse
|